Welcome to our dedicated page for PepGen news (Ticker: PEPG), a resource for investors and traders seeking the latest updates and insights on PepGen stock.
PepGen Inc. (Nasdaq: PEPG) is a clinical-stage biotechnology company dedicated to transforming the treatment of severe neuromuscular and neurologic diseases through innovative oligonucleotide therapeutics. The company's proprietary Enhanced Delivery Oligonucleotide (EDO) platform is designed to significantly enhance the uptake and activity of conjugated oligonucleotide therapeutics. This advanced platform leverages EDO peptides to optimize tissue penetration, cellular uptake, and nuclear delivery, enabling the transport of oligonucleotides into a variety of target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system.
PepGen’s leading product candidate is PGN-EDO51, which is currently being evaluated in the CONNECT1-EDO51 Phase 2 multiple ascending dose (MAD) clinical trial for the treatment of Duchenne muscular dystrophy (DMD) patients amenable to exon 51 skipping therapy. This trial marks a significant milestone as the first patient has been dosed, and initial data readout is expected in mid-2024. PGN-EDO51 has shown promising results in Phase 1 trials, demonstrating high levels of exon 51 skipping and a good safety profile.
Another key product in PepGen’s pipeline is PGN-EDODM1, which targets myotonic dystrophy type 1 (DM1). The FREEDOM-DM1 Phase 1 clinical trial is currently underway, with initial data anticipated in 2024. PGN-EDODM1 aims to restore cellular function by delivering a peptide-conjugated antisense oligonucleotide to address the root cause of DM1.
In addition to these, PepGen is developing PGN-EDO53 and PGN-EDO45 for other DMD patients, addressing exon 53 and 45 skipping, respectively.
Financially, PepGen has secured substantial backing through an $80 million underwritten offering of common stock, which will support ongoing research and clinical development. The company’s strategic partnerships with top-tier institutional investors and prominent biotech firms further strengthen its position in the market.
PepGen’s commitment to advancing therapeutic options for debilitating diseases is underscored by its ongoing research and development efforts, robust clinical pipeline, and strategic collaborations. The company continues to drive forward with the aim of delivering impactful therapies to patients with limited treatment options.
PepGen Inc. (Nasdaq: PEPG), a biotechnology company focused on oligonucleotide therapies, announced its participation in the 2023 American Academy of Neurology Annual Meeting from April 22-27 in Boston. The company will feature two oral and two poster presentations, highlighting advancements in treatments for Myotonic Dystrophy Type 1 (DM1) and Duchenne Muscular Dystrophy (DMD). Ashling Holland, Ph.D., will present preclinical data for DM1 on April 27, while two presentations on DMD will occur on April 23, showcasing results from a Phase 1 study of PGN-EDO51 and a study design for PGN-EDODM1. PepGen aims to revolutionize the treatment landscape for severe neuromuscular diseases through its Enhanced Delivery Oligonucleotide platform, demonstrating a commitment to addressing these critical health challenges.
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company, announced that its President and CEO, James McArthur, Ph.D., will present at the 22nd Annual Needham Virtual Healthcare Conference on April 20th, 2023, at 8:00 AM EDT. The presentation will be available for live streaming and will also be archived for one year on the company’s website. PepGen focuses on advancing next-generation oligonucleotide therapies aimed at severe neuromuscular and neurological diseases, utilizing its Enhanced Delivery Oligonucleotide (EDO) platform. This platform leverages over a decade of research to enhance the uptake and efficacy of oligonucleotide therapeutics through cell-penetrating peptides.
PepGen Inc. (Nasdaq: PEPG) reported its financial results for Q4 and full year 2022, highlighting significant advancements in its clinical pipeline. The company generated first-in-human data for PGN-EDO51, targeting Duchenne muscular dystrophy (DMD), and plans to initiate Phase 2 studies in 2023. Financially, PepGen reported a net loss of $69.1 million for 2022, an increase from $27.3 million in 2021. R&D expenses rose to $54.1 million, reflecting heightened clinical activities. The company has $181.8 million in cash, funding operations into early 2025. Overall, PepGen aims to develop transformative therapies for severe neuromuscular diseases.
PepGen Inc. (Nasdaq: PEPG) has presented promising clinical and nonclinical data for its Enhanced Oligonucleotide Delivery (EDO) platform at the MDA Conference in Dallas. The data highlights PGN-EDO51's ability to achieve a 34.9% exon skipping in non-human primates after four monthly doses, significantly higher than the 2.5% observed after a single dose. PepGen plans to initiate the CONNECT1-EDO51 Phase 2 study in DMD patients in the first half of 2023, with results expected in 2024. Additionally, the company aims to start the FREEDOM-DM1 Phase 1 study for myotonic dystrophy type 1 (DM1) patients in 2023, targeting safety and efficacy.
PepGen Inc. (Nasdaq: PEPG), a biotechnology company focused on oligonucleotide therapies, announced that its President and CEO, James McArthur, Ph.D., will present at Stifel’s CNS Days Conference on March 28, 2023, at 1:30 PM EST. The event aims to showcase PepGen's innovative approach to treating severe neuromuscular and neurological diseases through its Enhanced Delivery Oligonucleotide (EDO) platform, which leverages cell-penetrating peptides. A live webcast of the presentation will be available, with an archive for one year on PepGen's Investor Relations website.
FAQ
What is the current stock price of PepGen (PEPG)?
What is the market cap of PepGen (PEPG)?
What is PepGen Inc.?
What is the Enhanced Delivery Oligonucleotide (EDO) platform?
What are the key products in PepGen's pipeline?
What is the CONNECT1-EDO51 clinical trial?
What achievements has PGN-EDO51 demonstrated in trials?
What is the purpose of PGN-EDODM1?
How is PepGen funded?
What is Duchenne muscular dystrophy (DMD)?
What is myotonic dystrophy type 1 (DM1)?
What are PepGen’s future plans?
